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Abstract
Background An inadequate protein intake may offset the muscle protein synthetic response after physical activity, reducing
the possible beneﬁts of an active lifestyle for muscle mass. We examined the effects of 12 weeks of daily protein supplemen-
tation on lean body mass, muscle strength, and physical performance in physically active older adults with a low habitual pro-
tein intake (<1.0 g/kg/day).
Methods A randomized double-blinded controlled trial was performed among 116 physically active older adults [age 69
(interquartile range: 67–73) years, 82% male] who were training for a 4 day walking event of 30, 40, or 50 km/day.
Participants were randomly allocated to either 31 g of milk protein or iso-caloric placebo supplementation for 12 weeks. Body
composition (dual-energy X-ray absorptiometry), strength (isometric leg extension and grip strength), quadriceps contractile
function, and physical performance [Short Physical Performance Battery, Timed Up-and-Go test, and cardiorespiratory ﬁtness
(Åstrand–Rhyming submaximal exercise test)] were measured at baseline and after 12 weeks. We assessed vitamin D status
and markers of muscle damage and renal function in blood and urine samples before and after intervention.
Results A larger increase in relative lean body mass was observed in the protein vs. placebo group (Δ0.93 ± 1.22% vs.
Δ0.44 ± 1.40%, PInteraction = 0.046). Absolute and relative fat mass decreased more in the protein group than in the placebo
group (Δ0.90 ± 1.22 kg vs. Δ0.31 ± 1.28 kg, PInteraction = 0.013 and Δ0.92 ± 1.19% vs. Δ0.39 ± 1.36%, PInteraction = 0.029,
respectively). Strength and contractile function did not change in both groups. Gait speed, chair-rise ability, Timed Up-and-Go,
and cardiorespiratory ﬁtness improved in both groups (P < 0.001), but no between-group differences were observed. Serum
urea increased in the protein group, whereas no changes were observed in the placebo group (PInteraction < 0.001). No
between-group differences were observed for vitamin D status, muscle damage, and renal function markers.
Conclusions In physically active older adults with relatively low habitual dietary protein consumption, an improvement in
physical performance, an increase in lean body mass, and a decrease in fat mass were observed after walking exercise training.
A larger increase in relative lean body mass and larger reduction in fat mass were observed in participants receiving 12 weeks
of daily protein supplementation compared with controls, whereas this was not accompanied by differences in improvements
between groups in muscle strength and physical performance.
Keywords Elderly; Protein; Body composition; Muscle; Randomized clinical trial
Received: 4 July 2018; Accepted: 18 December 2018
*Correspondence to: Maria T. E. Hopman. Department of Physiology (392), Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500
HB Nijmegen, The Netherlands. Email: maria.hopman@radboudumc.nl
ORIG INAL ART ICLE
© 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 298–310
Published online 7 March 2019 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12394
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
Introduction
A physically active lifestyle attenuates the age-related loss of
muscle mass (i.e. sarcopenia) and associated decrements of
muscle function1,2 by increased muscle protein synthesis
rates after exercise but also due to preservation of skeletal
muscle sensitivity to dietary amino acids and suppressing
the catabolic inﬂammatory cytokines in the muscle.3–5 Sufﬁ-
cient protein intake is another vital component to maintain
and regain muscle mass.6–8 Current recommendations for
adults advice 0.8 g/kg/day.9 However, the PROT-AGE study
group suggested that older adults above 65 years of age
should consume 1.0–1.2 g/kg/day to compensate for the at-
tenuated capacity of protein utilization in the aging muscles.6
For physically active older adults, their recommendation is
even higher, i.e. ≥1.2 g/kg/day in order to comply with the
synergistic effects of exercise and protein intake on muscle
protein synthesis.6 It has previously been shown that more
than 50% of physically active older adults has a protein intake
below 1.2 g/kg/day.10 This observation suggests that physi-
cally active older adults may not consume enough protein
to be utilized for the exercise-induced improved muscle pro-
tein synthetic response and, thus, to prevent age-related
muscle mass loss.
Therefore, we assessed the effects of 12 weeks of daily
protein supplementation on lean body mass, muscle
strength, and physical performance in physically active older
adults with a low habitual protein intake. We hypothesized
that protein supplementation in physically active older adults
would induce beneﬁcial effects on lean body mass, muscle
strength, and physical performance, while no effects were ex-
pected in the control group receiving an iso-caloric placebo.
Methods
Participants
Participants were recruited between 16 March 2017 and 12
April 2017 via the Nijmegen Exercise Study database (Study-
ID: NL36743.091.1111) and social media. Interested men and
women of at least 65 years old were included if they (i) had
a habitual protein intake ≤1.0 g/kg/day based on a 123 item
online food frequency questionnaire12 calculated using the
Dutch Food composition database of 2010,13 (ii) were regis-
tered and in training for the 2017 Nijmegen Four Days
Marches [an annual 4 day walking event (30, 40, or
50 km/day) in the Netherlands; https://www.4daagse.nl/
en], and (iii) were able to understand and perform the study
procedures. Exclusion criteria for participation in the study
were type 1 or type 2 diabetes mellitus (non-fasted state
>11 mmol/L), allergic or sensitive for milk proteins or lactose
intolerant, Chronic Obstructive Pulmonary Disease (COPD), cancer,
renal insufﬁciency [estimated glomerular ﬁltration rate
(eGFR) < 30 mL/min/1.73 m1], intestinal diseases that may
inﬂuence the uptake of protein, use of statins, and involved in a
heavy resistance type exercise programme. All participants signed
an informed consent form prior to any experimental procedure.
The study conformed to the principles of the Declaration of
Helsinki andwas approved by aMedical Ethical committee, the In-
dependent Review Board Nijmegen (Study-ID: NL60137.072.16).
This trial was registered at www.trialregister.nl as NTR6488.
Design
In a double-blind, controlled intervention study, a total of 116
eligible participants were randomly allocated to either the
protein-supplemented or the placebo-supplemented group.
An independent researcher randomized the study partici-
pants by means of computer-generated random numbers
with a block size of 10 in a 1:1 ratio. Before and after 12weeks
of supplementation, anthropometrics, dual-energy X-ray ab-
sorptiometry (DXA), strength measurements (maximal iso-
metric leg extension and handgrip strength), and physical
performance measurements [Short Physical Performance
Battery (SPPB), Timed Up-and-Go (TUG), and the Åstrand–
Rhyming submaximal exercise test] were performed. Addi-
tional muscle function measurements were performed in a
subgroup of 30 participants of the protein group and 30 par-
ticipants of the placebo group. Blood samples, dietary intake
(24 h recall), and physical activity (Short Questionnaire to As-
sess Health enhancing physical activity) data were collected
from all participants. In addition, participants were invited
to complete an online diary every week, reporting their daily
supplement intake and training kilometres (walking) for the
Nijmegen Four Days Marches.
Protein intervention
Participants were asked to consume either a 250 mL protein
supplement or a 250 mL iso-caloric placebo drink, twice a
day. Two packages of the protein supplement (500 mL)
contained in total 36.8 g milk protein concentrate (MPC 80)
with 31 g protein, 1.1 g fat, and 14.5 g lactose (carbohy-
drates), whereas 500 mL of the placebo supplement
contained 1.1 g protein, 5.2 g fat, and 36 g of carbohydrates
(FrieslandCampina Consumer Products Europe, Wageningen,
the Netherlands). Protein and placebo supplements were
provided in ready-to-drink non-transparent packages of
250 mL and were vanilla ﬂavoured to mask contents. Partici-
pants were asked to consume one beverage during breakfast
and one beverage within 30 min after exercise (e.g. walking).
On non-exercising days, participants were instructed to con-
sume the second beverage during lunch. Participants were
asked to report their daily supplement intake every week.
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Compliance was calculated by dividing the number of used
supplements by the total supplements and multiplied by
100. Adverse events were documented.
Measurements
Body composition
Height and weight (Seca 888 scale, Hamburg, Germany) were
measured and used to calculate the body mass index. Total
and regional lean body mass and fat mass of the participants
were measured by DXA (Lunar Prodigy Advance DXA; GE
Healthcare, Madison, WI, USA). The DXA scans were per-
formed with dual-energy beam (0.03 mrem) and a scan time
of approximately 10 min.
Handgrip strength
Handgrip strength of the dominant hand was measured with a
hydraulic, analogue handheld dynamometer (Jamar®, Jackson,
MI, USA). For every participant, the dynamometer was ad-
justed to their hand size. The participants were seated in a chair
without arm rests with the elbow ﬂexed in a 90° angle position
and were asked to shortly maximally squeeze the handgrip in-
strument three times with 1 min rest between measurements.
The maximum strength in kilograms was used for analysis.
Quadriceps strength and contractile function
Additional validated muscle characteristic measurements14
were performed in a subgroup of 30 participants of the pro-
tein group and 30 participants of the placebo group. Muscle
strength was measured by performing three to six isometric
maximal voluntary contractions (MVCs) of the dominant
quadriceps femoris muscle for approximately 3 s.15 The force
signal was ampliﬁed (strain indicator type CA660, Peekel In-
struments, Rotterdam, the Netherlands), digitized (1000 Hz),
and stored. The highest MVC was expressed absolute and rel-
ative to body weight. Electrically stimulated quadriceps mus-
cle contractions were obtained at 40% of the MVC with 1 s
50 Hz electrical impulses generated by a direct-current high-
voltage stimulator (DS7A, Digitimer Ltd, Hertfordshire, UK),
through two surface electrodes on the distal and proximal
part of the anterior thigh (Electro-Medical Supplies,
Greenham Ltd, Wantage, Oxfordshire, UK) to assess voluntary
muscle strength, function, and fatigue.15 A force–frequency
relationship of only the valid measurements that were not
limited by technical constraints was obtained through peak
force generation upon ﬁve 1 s stimulation frequencies (1,
10, 30, 50, and 100 Hz, respectively). Contraction and relaxa-
tion rates were calculated as indices of muscle speed of the
average of 1, 30, 50, and 100 Hz impulse; normalized maximal
rate of force rise was expressed as the maximal slope of force
increment as percentage of peak force,16 and early and half
relaxation time was deﬁned as the time taken for force to de-
cline from 75% to 50% and from 50% to 25% of the peak force,
respectively. Resistance to fatigue was assessed by activating
the quadriceps muscle repetitively using 30 Hz bursts with a
1 s duration every 2 s for 2 min. Only the valid muscle fatigue
resistance measurements were expressed as a percentage of
average force of the last three contractions from the average
force of the ﬁrst three contractions, and the peak force per
repetition was analysed.
Short Physical Performance Battery
Physical performance was assessed using the SPPB, which is
considered a reliable and valid method in older adults.17
The SPPB consists of three components for which 0–4 points
could be earned: balance, gait speed, and chair-rise ability.
Participants’ balance was assessed by examining their ability
to stand still for 10 s with their feet side by side, in semi-
tandem and in tandem position. Gait speed was determined
by the time necessary to complete a walk of 4 m on their
usual gait speed. The chair-rise ability score was determined
by the time necessary to rise out of a chair and sit down ﬁve
times in a row, without aid of arms. For gait speed and chair-
rise ability, the quickest time out of two attempts was re-
ported. A SPPB total score (0–12 points) was calculated by
summing the scores.
Timed Up-and-Go test
During the TUG test, the participants were instructed to rise
from a chair, walk 3 m, turn around, walk back, and sit down
again as quickly as possible.18,19 The time was reported after
one trial run.
Åstrand–Rhyming test
To evaluate cardiorespiratory ﬁtness, participants performed
the Åstrand–Rhyming submaximal exercise test on a station-
ary bicycle. The test was performed on a mechanically braked
cycle ergometer (Corival model, Lode Holding Company BV,
the Netherlands), and heart rate was measured with a Polar
(Polar Electro, RS400 and RS800 model, Kempele, Finland).
The maximal volume of oxygen consumption (VO2max) was
estimated by applying the work rate and mean heart rate of
the 5th and 6th minute to the Åstrand normogram, with cor-
rection for weight and age.20,21
Physical activity
Habitual physical activity was assessed at baseline by the
Short Questionnaire to Assess Health enhancing physical ac-
tivity questionnaire, which is considered a valid and reliable
method in older adults.22 This self-administered question-
naire estimates habitual level of physical activity during a nor-
mal week over the past month, with questions about the
type, duration, and frequency of activities. Total physical ac-
tivity and exercise-speciﬁc activities were calculated in meta-
bolic equivalent of task hours per day by multiplying the
exercise time in hours with the accompanying metabolic
equivalent of task score of the activity.23 Moreover, partici-
pants reported their weekly walking exercise (in kilometres)
as a training for the Nijmegen Four Days Marches.
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Dietary intake
Daily dietary intake was assessed using a repeated 24 h
recall, which is a validated method to assess the amount
and distribution of protein intake.24 Two recall days
were randomized over the week with the restriction that
no participant was assigned to two identical week days
or two weekend days. The 24 h recall was performed
face to face or by phone by trained dieticians and coded
by the same dieticians into the web-based program
Compl-eat, which calculated the dietary intake using
the Dutch Food Composition Database of 2016.25 The
mean of the two recorded days represented the daily di-
etary intake.
Blood samples
Non-fasted venous blood was drawn from the antecubital
vein before and after the supplementation period, and serum
and lithium heparin samples were stored at 80°C until anal-
ysis. Non-fasting glucose and creatinine levels were assessed
to calculate eGFR and were analysed at baseline to exclude
participants suffering from insulin resistance, type II diabetes,
and renal insufﬁciency. To check protein intake and renal
function before and after the supplementation period, we
assessed urea, creatinine, and albumin concentrations. More-
over, we assessed creatine kinase to identify if muscle damage
occurred.26 Vitamin D status, C-reactive protein (CRP), and in-
terleukin (IL)-6 and IL-10 were assessed, because of their pos-
sible confounding effects on muscle mass.27,28 Glucose,
creatinine, urea, albumin, creatine kinase, and CRP were mea-
sured using Siemens Dimension Vista 1500 (Siemens
Healthcare Diagnostics Inc., Tarrytown, New York, USA). Se-
rum 25-hydroxyvitamin D concentrations were measured
using liquid chromatography coupled to tandem mass spec-
trometry detection (Waters Chromatography B.V., Etten-Leur,
the Netherlands). Serum IL-6 and IL-10 concentrations were
determined using a multiplex electroluminescence-based cy-
tokine assay on a MESO QuickPlex SQ120 plate imager (Meso
Scale Diagnostics, Rockville, Maryland, USA). Analysis were
performed by trained technicians using standard operating
procedures, on a single day using the same calibration and
set-up to minimize variation.
Urine analysis
Upon arrival in the laboratory, a urine sample (5mL) was pro-
vided by all participants and was frozen and stored at 80°C.
After completion of the study baseline and post-
supplementation, albumin and creatinine were determined
to assess renal function using Dimension Vista 1500 (Siemens
Healthcare Diagnostics Inc.).
Statistical analysis
Based on a Type I error of 0.025 and a power of 90%, we cal-
culated (G-power, version 3.1.2, University of Dusseldorf,
Germany) that 53 participants per study arm were
needed to ﬁnd an expected difference in changes in
quadriceps strength of 5 ± 5 kg and 0.41 ± 0.65 in SPPB
score between the protein and placebo group.29 To ac-
count for potential dropout (~10%), we recruited 58 par-
ticipants per study arm in our study. Statistical analyses
were performed using SPSS 22.0 software (IBM SPSS Sta-
tistics for Windows, Version 22.0 IBM Corp., Armonk,
NY, USA). A per-protocol analysis was used including
only those participants with a compliance rate of ≥90%.
All continuous variables were visually inspected and
tested for normality with the Shapiro–Wilk test. Partici-
pant characteristics were displayed as mean ± standard
deviation or mean ± standard error or median [inter-
quartile range (IQR)] for parametric and non-parametric
continuous variables, respectively, and as number of par-
ticipants with percentages for categorical variables.
Baseline characteristics between groups were
compared by means of an independent-samples t-test
or a Mann–Whitney U-test for parametric or non-
parametric continuous variables, respectively, or with a
chi-square test for categorical variables. Data from be-
fore and after the supplementation period were
analysed by using repeated-measures analysis of vari-
ance with time as a within-subjects factor and treatment
as a between-subjects factor. Because no between-group
differences were found at baseline, no variables were
added as a confounder in the main analysis. The level
of signiﬁcance was set at P < 0.05 (two-sided).
Results
Participants
For this study, 177 participants were screened, and 116 par-
ticipants were included in the study and randomly allocated
to the protein or placebo group. One participant had elevated
blood glucose levels and was therefore excluded from the
study, and another participant dropped out after 2 weeks
due to gastrointestinal complaints (Figure 1). There were no
differences between the protein and placebo groups for any
of the baseline characteristics (Table 1). Almost all partici-
pants were Caucasian, except for one Asian participant in
the protein group. Six participants experienced gastrointesti-
nal complaints during the supplementation period (three par-
ticipants of the protein group and three participants of the
placebo group) but did not drop out. There were no serious
adverse events reported during the supplementation period.
Compliance of supplementation intake was high and did not
differ between the protein and placebo groups (96 ± 3%
and 95 ± 3%, respectively).
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Protein intake
Protein intake was comparable between the protein and
placebo groups at baseline (P = 0.18), with more than
60% of the proteins derived from animal proteins in both
groups (Table 1). A signiﬁcant increase in protein intake
(i.e. excluding supplements) was observed over time
(PTime = 0.034), but no differences were observed between
groups (Table 2). Daily energy and macronutrient intake did
not differ between groups at baseline and did not change
over time (Tables 1 and 2). Taking into account the protein
supplements, total protein intake increased in the protein
group to 1.29 ± 0.28 g/kg/day during the 12 week supple-
mentation period.
Physical activity
Participants of the protein and control group reported a
similar physical activity volume at baseline (Table 1). All partic-
ipants performed walking exercise training as a preparation
for the Nijmegen Marches. Signiﬁcant changes over time were
observed in training kilometres (PTime < 0.001, Figure 2), but
no between-group differences were observed (PInteraction = 0.85).
The sum of walking kilometres during the 12 weeks of the study
was not different between groups [protein: 391 (IQR: 286–512)
km vs. placebo: 338 (IQR: 239–493) km, P = 0.31].
Body composition
Total body weight decreased borderline signiﬁcantly more in the
protein group compared with the placebo group (Table 3).
Whole-body lean mass increased in the protein group as well
as in the placebo group following 12 weeks of supplementation
(Table 3). The protein group had a larger relative
increase in whole-body lean mass than the placebo group
(Table 3, Figure 3). Truncal lean body mass increased sig-
niﬁcantly more in the protein group compared with the
placebo group (PInteraction = 0.007, Table S1). Total body
fat mass decreased in both groups but signiﬁcantly more
in the protein group compared with the placebo group
(Table 3). Furthermore, fat mass/lean body mass ratio
was signiﬁcantly more reduced in the protein group com-
pared with the placebo group (Table 3).
Figure 1 CONSORT ﬂow diagram illustrating the movement of participants through the study, which was conducted between March 2017 and July
2017.
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Table 1 Baseline characteristics of participants in the protein and placebo group
Total group Protein Placebo
P-valuen = 114 n = 58 n = 56
Demographics
Age (years) 69 (67–73) 69 (67–72) 69 (67–73) 0.82d
Men, n (%) 93 (82) 47 (81) 46 (82) 0.88e
Body composition
Body weight (kg) 83.1 ± 10.4 84.6 ± 10.2 81.5 ± 10.5 0.11c
BMI (kg/m2) 26.8 ± 2.6 27.2 ± 2.6 26.3 ± 2.5 0.05c
Waist-to-hip ratio 0.94 ± 0.08 0.95 ± 0.07 0.94 ± 0.08 0.42c
Diet
Energy intake (kcal) 1944 ± 533 1919 ± 534 1970 ± 536 0.61c
Protein intake (g/kg/day) 0.89 ± 0.23 0.86 ± 0.23 0.92 ± 0.24 0.18c
Animal protein (%) 61.2 ± 11.1 61.5 ± 11.4 61.1 ± 10.9 0.73c
Plant protein (%) 38.8 ± 11.1 38.5 ± 11.4 39.0 ± 10.9 0.73c
Protein (en%) 16.0 ± 3.4 16.2 ± 3.1 15.7 ± 3.6 0.44c
Fat intake (en%) 35.6 ± 6.7 35.7 ± 7.0 35.5 ± 6.5 0.88c
Carbohydrate intake (en%) 42.3 ± 7.3 42.4 ± 8.1 42.1 ± 6.4 0.81c
Physical activity
Total physical activity (METh/week) 117.7 (81.7–173.5) 109.0 (79.1–142.1) 124.0 (87.3–186.1) 0.14d
Domestic work activities (METh/week) 26.3 (11.3–45.1) 22.5 (6.3–41.4) 29.5 (15–48.2) 0.14d
Commuting activities (METh/week)a 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.73d
Leisure time activities (METh/week) 53.4 (38.3–73.1) 50.8 (33.0–70.0) 59.3 (39.9–77.9) 0.22d
Sports activities (METh/week) 21.0 (3.4–41.2) 21.0 (0.0–39.7) 18.2 (7.8–51.0) 0.74d
Blood analysis
eGFR (mL/min/1.73 m1) 81.2 ± 11.6 79.4 ± 13.5 83.0 ± 9.1 0.11c
Non-fasted glucose (mmol/L)b 5.8 ± 1.1 5.7 ± 1.1 5.8 ± 1.2 0.52c
25(OH)D (nmol/L)b 73.7 ± 27.2 73.7 ± 28.9 73.8 ± 25.6 0.98c
CRP (mg/L) 3.9 ± 3.3 4.0 ± 3.8 3.7 ± 2.9 0.66c
IL-6 (pg/mL) 1.02 ± 2.71 0.64 ± 0.44 1.41 ± 3.82 0.13c
IL-10 (pg/mL) 0.305 ± 0.438 0.327 ± 0.446 0.282 ± 0.431 0.58c
Data are presented as number (percentage) of participants, mean ± standard deviation, or median (interquartile range). BMI, body mass
index; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; en%, energy percentage; IL, interleukin; 25(OH)D, 25-
hydroxyvitamin D; MET, metabolic equivalent of task.
an = 22.
bn = 113.
cDerived by independent-samples t-test.
dDerived by Mann–Whitney U-test.
eDerived by chi-square test.
Table 2 Changes in habitual dietary intake of participants in the protein and placebo group (disregarding supplements)
Protein Placebo
P-valuen = 58 n = 56
Pre Post Change Pre Post Change Time Treatment Interaction
Energy intake (kcal) 1919 ± 534 1841 ± 456 77.8 ± 484.5 1970 ± 536 1960 ± 492 10.4 ± 535.6 0.36 0.30 0.48
Protein intake
(g/kg/day)
0.86 ± 0.23 0.92 ± 0.27 0.06 ± 0.27 0.92 ± 0.24 0.97 ± 0.23 0.05 ± 0.28 0.034 0.18 0.74
Protein intake
at breakfast (g)
11.3 ± 4.8 11.8 ± 7.6 0.5 ± 7.0 12.9 ± 7.7 13.4 ± 7.2 0.3 ± 8.1 0.62 0.17 0.90
Protein intake at
lunch (g)
21.7 ± 10.2 20.3 ± 14.5 3.7 ± 9.3 18.3 ± 7.8 20.7 ± 9.5 2.5 ± 11.6 0.57 0.61 0.003
Protein intake
at dinner (g)
31.0 ± 10.8 33.8 ± 16.8 2.8 ± 19.5 36.0 ± 14.1 37.4 ± 13.4 1.7 ± 21.3 0.25 0.014 0.77
Protein (en%) 16.2 ± 3.1 16.8 ± 3.8 0.6 ± 3.8 15.7 ± 3.6 16.4 ± 3.0 0.7 ± 3.9 0.07 0.41 0.88
Fat (en%) 35.7 ± 7.0 35.5 ± 7.1 0.2 ± 8.0 35.5 ± 6.5 36.6 ± 6.4 1.1 ± 7.5 0.53 0.64 0.36
Carbohydrate
(en%)
42.4 ± 8.1 42.6 ± 7.7 0.1 ± 8.6 42.1 ± 6.4 40.9 ± 7.4 1.2 ± 8.0 0.51 0.40 0.40
Data are presented as mean ± standard deviation. Bold values indicate P-value <0.05. en%, energy percentage.
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Muscle strength and contractile function
Handgrip strength was not improved in both groups after the
supplementation period (Table 3). Subgroup measurements
of maximal voluntary quadriceps contraction demonstrated
also no changes (Table 3). Electrically stimulated quadriceps
muscle peak contractions to 1, 10, 30, 50, and 100 Hz for
the two groups are shown in Figure 4, and no between-group
differences were observed at baseline or over time. Maximal
rate of force rise and early and half relaxation time were not
different between groups over time (Table 3), indicating that
no differences occurred in velocity response of the muscle.
Muscle fatigue, the signiﬁcant decline in force of the quadri-
ceps muscle during 2min of electrical stimulation, did not dif-
fer between groups at baseline and after the supplementation
period (Figure 5). Finally, no changes in resistance to fatigue
after 2 min of electrical stimulation were found in both
groups (Table 3).
Physical performance
No signiﬁcant change in total SPPB score was observed in
both the protein and placebo group after the intervention
(Table 3). After 12 weeks, both groups showed faster gait
speed (PTime < 0.001), faster chair-rise ability (PTime < 0.001),
faster TUG (PTime < 0.001), and increased estimated VO2max
(PTime < 0.001), but no differences between groups were ob-
served in any of the SPPB subscores, TUG, or estimated
VO2max (Table 3).
The effects of 12 weeks of daily protein vs. placebo supple-
mentation on body composition, muscle strength, and physi-
cal performance are separately given for men and women in
Table S2A and S2B.
Biochemical measures
Renal function (eGFR), glucose levels, and inﬂammatory markers
(CRP, IL-6, and IL-10) were similar at baseline (Table 1). At base-
line, 79% of the protein group and 84% of the placebo group had
a serum 25-hydroxyvitamin D of ≥50 nmol/L. The vitamin D se-
rum levels increased in both groups (PTime = 0.001), but no
between-group differences were observed (Table 3). In both
the protein and placebo groups, creatinine concentrations in-
creased, andeGFRdecreasedafter12weeks (bothPTime<0.001),
but no between-group differences were observed (Table 3).
Serum urea, a breakdown product of protein, increased follow-
ing 12 weeks of protein supplementation in the protein group,
whereas no changes were observed in the placebo group (Table
3). No differences were observed between groups for serum cre-
atine kinase, serum albumin, and urinary albumin/urinary creat-
inine ratio following 12 weeks of supplementation (Table 3).
Discussion
The present randomized double-blind placebo-controlled trial
revealed novel ﬁndings about the beneﬁts of 12 weeks protein
supplementation in physically active older adults with a low ha-
bitual dietary protein intake. First, we found a larger relative in-
crease in lean body mass and a larger decrease in fat mass in the
protein intervention group vs. control group. However, no dif-
ferences in muscle strength, muscle contractile properties, and
physical performance were found over time between groups.
These ﬁndings suggest that age-related loss of muscle mass
can be delayed with an increased protein intake in physically ac-
tive older adults who have a relatively low habitual protein in-
take, while no changes were observed in muscle function.
Twelve weeks of protein supplementation induced a rela-
tive increase of whole-body lean mass by 0.93 ± 1.22% and a
concomitant decrease in fat mass in physically active older
adults, which was larger than changes observed in the placebo
group. These results are in line with previous studies that in-
vestigated the beneﬁts of protein supplementation in frail
older adults,30–32 while studies assessing the effect of protein
supplementation in community-dwelling older adults found
contradicting results. Whereas some studies in community-
dwelling older adults found improvements of lean body mass
with protein supplementation,33–35 others did not ﬁnd such
beneﬁcial effects.36,37 A potential explanation for these dis-
crepant ﬁndings may relate to differences in the included par-
ticipants. We speciﬁcally selected physically active older
adults with a low habitual protein intake based on the FFQ.
It has been shown that regular exercise training stimulates
muscle protein synthesis, but the muscle protein balance re-
mains negative in the absence of sufﬁcient protein intake.38
Hence, community-dwelling older adults that are not as
active as our participants may not beneﬁt from protein
Figure 2 Training walking exercise plotted for every week in kilometres
for the protein group, n = 58, black lines and for the placebo group,
n = 56, grey lines. The training kilometres signiﬁcantly changed over time
(PTime < 0.001), but no between-group differences were observed
(PInteraction = 0.85). Data are presented as mean ± standard error.
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supplementation as there is insufﬁcient stimulus for mus-
cle synthesis. Alternatively, we supplemented our physi-
cally active participants with 15 g protein at breakfast
and 15 g protein after exercise or at lunch, causing a sig-
niﬁcant increase in daily protein intake from
0.86 ± 0.23 g/kg/day upon enrolment to 1.29 ± 0.28 g/
kg/day at 12 weeks. This level of protein intake aligns
with guideline recommendations for physically active
older adults6 and seemed sufﬁcient to attenuate the
age-induced loss of muscle mass in previous studies.39–41
The increase in lean body mass and decrease in fat mass
were predominantly observed in the trunk. These ﬁndings
are in alignment with previous studies that revealed an in-
crease in trunk lean body mass following aerobic exercise
training, whereas resistance exercise also increased appen-
dicular lean body mass.42,43 Our participants of both the
Figure 3 Boxplots showing changes in relative total lean body mass (A) and relative total fat mass (B) in the protein group (dark grey) and placebo
group (light grey). There was a signiﬁcantly larger increase in relative total lean body mass (PInteraction = 0.046) and a signiﬁcantly larger decrease in
relative total fat mass in the protein group compared with the placebo group (PInteraction = 0.029). Boxplots show the median, upper and lower quar-
tiles, and the maximum and minimum values.
Figure 4 Force responses to different stimulation frequencies (1, 10, 30, 50, and 100 Hz) are given in absolute forces (A and B) and normalized for peak
isometric 100 Hz force (relative) (C and D) at baseline and after the supplementation period for the protein group, n = 20 (A and C) and for the placebo
group, n = 24 (B and D). At baseline, the absolute and relative peak forces of the quadriceps were similar between the protein and placebo groups
(PInteraction = 0.75 and PInteraction = 0.75, respectively). After the supplementation, again no between-group differences were observed in the absolute
and relative quadriceps peak forces (PInteraction = 0.33 and PInteraction = 0.20, respectively). Data are presented as mean ± standard deviation.
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protein and placebo groups mainly performed moderate in-
tensity walking exercise, which might explain the trunk-
speciﬁc improvements in both groups. The improvements
were however signiﬁcantly larger in the protein group. Vari-
ous health beneﬁts have been associated with truncal body
composition improvements, such as a reduced risk for cardio-
vascular diseases and metabolic syndrome,44 improved pos-
tural stability, and consequently a reduced risk for falls,45,46
while the maintenance of lean mass of the trunk may only
moderately contribute to the mobility of older adults.47
We did not ﬁnd improvements in hand grip strength, nor in
quadriceps muscle strength, contractile function and fatigue
following protein supplementation. These muscle characteristics
all apply to appendicular muscles, while lean body mass mainly
increased in the trunk region, which may partly explain the lack
of improvements seen in these muscles. Lean body mass
improvements are certainly not always accompanied by changes
in muscle strength,39 as sometimes, the muscular hypertrophy is
not induced by myoﬁbrillar hypertrophy but by sarcoplasmic
hypertrophy.48 The latter consists of growth of the sarcoplasm
and non-contractile proteins, thus not directly contributing to
muscular force.48 Because no biopsies were performed in our
volunteers, the identiﬁcation of the compartment that
accumulates proteins cannot be addressed in this study.
While both groups increased their cardiorespiratory ﬁtness,
most likely as a result of the increased walking exercise training
kilometres, no between-group differences were observed. A
previous study showed positive effects of protein supplementa-
tion on changes in VO2max among participants aged
48 ± 7 years.49 However, the participants of the treatment
group included in that study were untrained and had lower car-
diorespiratory ﬁtness scores at baseline compared with the
baseline values of estimated VO2max of our participants
(25.5 ± 4.2 mL/kg/min vs. 31.1 ± 9.9 mL/kg/min, respectively).
Untrained participants may beneﬁt more from protein supple-
mentation for improvement of aerobic ﬁtness, than physically
active older adults do.50
Although physical performance as measured with SPPB and
TUG improved in both groups after 12 weeks, most likely as a
result of the increased walking exercise training kilometres,
protein supplementation had no additional impact on these
changes. The beneﬁcial effects of a physically active lifestyle
might therefore bemore pronounced and overrule the beneﬁts
of enhancing the protein intake. A study performed in active
older men found no additional effect of protein supplementa-
tion above the effect of resistance exercise training51 indicating
that the effect of exercise is larger than the effect of protein in-
take.38 However, the active older men that were studied had
an adequate protein intake (1.14 ± 0.05 g/kg/day) already.
The results of our study suggest that improving the protein in-
take in healthy active elderly with an inadequate habitual pro-
tein intake can enlarge the health beneﬁts of an active
lifestyle by increasing lean body mass. Moreover, it should be
noted that the physically active older adults in our study exhib-
ited already a high level of physical performance at baseline
[median: 12 (IQR: 11–12) with 65% of the participants demon-
strating the maximum score of 12 points at baseline], and con-
sequently, it was likely that a ceiling effect occurred for most
participants. Therefore, SPPB may not be an adequate test in
this active group to assess the effect of additional protein sup-
plementation.52 In parallel, the TUG test reports in community-
dwelling older adults average scores between 7.9 and 9.0 s,53,54
whereas our participants already scored 6.9 ± 0.9 s at baseline,
thus creating a small window for improvement. Therefore, we
should be cautious with our ﬁndings that protein supplementa-
tion had no effect on physical performance because our tests
used may not have been suitable for such an active population.
Alternative tests such as 400 m walk test generally give more
information in high-functioning participants52 and are recom-
mended to be incorporated in future studies.
The results of the present study suggest that physically ac-
tive older adults with a low habitual protein intake could gain
almost 1% in lean body mass following 12 weeks of protein
supplementation of 31 g/day. The average rate of annual loss
Figure 5 Force responses plotted every second during the fatigue protocol at baseline (t0) and after the supplementation period (t1) for the protein
group, n = 14 (A) and for the placebo group, n = 16 (B). At baseline, the decline in force of the quadriceps was similar between the protein and placebo
groups (PInteraction = 0.17). For both groups, a signiﬁcant decline in quadriceps force was observed at baseline and after the supplementation (all
PTime < 0.001). After the supplementation, again no between-group differences were observed in the decline in quadriceps force (PInteraction = 0.27).
Data are presented as mean ± standard deviation.
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of muscle mass in older adults is normally approximately 0.5–
1.0%.40 Thus, the increase of lean body mass found in the
protein group could be translated into saving 1–2 years of
muscle mass decline and is therefore of great signiﬁcance
for daily life mobility on the long term. The enhanced protein
intake did not seem to affect renal function throughout the
supplementation period because no differences in eGFR were
observed compared with the placebo group and no changes
in urinary albumin/urinary creatinine ratio were seen over
time. Therefore, enhancing protein intake is not only effec-
tive but also a safe strategy55 to attenuate the age-related
loss of muscle mass in physically active older adults.
We performed a double-blinded randomized placebo-
controlled trial in a large study population with a low dropout
rate and high compliance. However, some limitations should
be noted. Our physical performance measurements were most
likely not sensitive enough to distinguish improvements be-
tween both groups of high-functioning participants. Further-
more, we did not collect 24 h urine in which creatinine could
be determined, the gold standard to assess renal function. How-
ever, with other parameters such as serum eGFR and urinary
albumin/urinary creatinine ratio, we were able to determine
that renal function was unaffected by the supplementation.
We performed explorative sex-speciﬁc analyses of our data
and found that the beneﬁcial effects of protein supplementation
on body composition are more pronounced in women than in
men. We acknowledge that our study was not powered for
these sub-analyses, but the outcomes suggest that more studies
are warranted to assess possible differences between men and
women in responses to protein supplementation.
Conclusions
In physically active older adults with relatively low habitual di-
etary protein consumption, an improvement in physical per-
formance, an increase in lean body mass, and a decrease in
fat mass were observed after walking exercise training.
Twelve weeks of protein supplementation resulted in a rela-
tive larger increase in lean body mass and a larger decrease
in fat mass compared with the placebo group. This was how-
ever not accompanied by differences in improvements in
muscle strength or physical performance between both
groups. The improved body composition shows that protein
supplementation enlarges the proposed health beneﬁts of
an active lifestyle in physically active older adults, but physical
performance could not be improved further in already vital
older adults.
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